• 1
    Haythornthwaite JA, Heinberg LJ, McGuire L. Psychologic factors in scleroderma. Rheum Dis Clin North Am 2003; 29: 42739.
  • 2
    Malcarne VL. Psychological adjustment in systemic sclerosis. In: ClementsPJ, FurstDE, editors. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 33150.
  • 3
    Osoba D, King M. Meaningful differences. In: FayersP, HaysRD, editors. Assessing quality of life in clinical trials. New York: Oxford; 2005. p. 24457.
  • 4
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 5
    Garber AM, Weinstein MC, Torrance GW, Kamlet MS. Theoretical foundations of cost-effectiveness analysis. In: GoldMR, SiegelJE, RussellLB, WeinsteinMC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p. 2553.
  • 6
    Conditional expected utility. In: KrantzD, LuceR, SuppesP, TverskyA, editors. Foundations of measurement. New York: Academic Press; 1971. p. 369421.
  • 7
    Von Neumann J, Morgenstern O. Theory of games and economic behavior. New York: Wiley; 1953.
  • 8
    Kind P. Values and valuation in the measurement of HRQOL. In: FayersP, HaysRD, editors. Assessing quality of life in clinical trials. New York: Oxford; 2005. p. 391404.
  • 9
    Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 130.
  • 10
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592600.
  • 11
    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 83240.
  • 12
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 13
    Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 14
    Clements PJ. Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 116.
  • 15
    Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient- generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 198491.
  • 16
    Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 384401.
  • 17
    Ware JE Jr, Kosinki M, Keller S. SF-36 Physical and mental health summary scales: a user's manual. Boston: New England Medical Center Health Institute; 1994.
  • 18
    Ware J, Kosinski M, Dewey J. How to score version two of the SF-36 Health Survey. Lincoln (RI): QualityMetric Inc.; 2000.
  • 19
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 20
    Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-Penicillamine Study. Ann Rheum Dis 2006; 65: 13259.
  • 21
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001; 44: 65361.
  • 22
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the Disability Index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999; 42: 237280.
  • 23
    Schulberg HC, Saul M, McClelland M, Ganguli M, Christy W, Frank R. Assessing depression in primary medical and psychiatric practices. Arch Gen Psychiatry 1985; 42: 116470.
  • 24
    Coulehan JL, Schulberg HC, Block MR. The efficiency of depression questionnaires for case finding in primary medical care. J Gen Intern Med 1989; 4: 5417.
  • 25
    Clinical Informatics Research Group. UMaker User's Manual, UMDNJ Technical Report. Picastaway (NJ): UMDNJ; 1999.
  • 26
    Arias E. United States life tables, 2002. Natl Vital Stat Rep 2004; 53: 138.
  • 27
    Stalmeier PF, Goldstein MK, Holmes AM, Lenert L, Miyamoto J, Stiggelbout AM, et al. What should be reported in a methods section on utility assessment? Med Decis Making 2001; 21: 2007.
  • 28
    Stalmeier PF. Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments. Med Decis Making 2002; 22: 5364.
  • 29
    Franzblau AN. A primer of statistics for non-statisticians. New York: Harcourt, Brace & World; 1958.
  • 30
    Malcarne VL, Greenbergs HL. Psychological adjustment to systemic sclerosis. Arthritis Care Res 1996; 9: 519.
  • 31
    Cossutta R, Zeni S, Soldi A, Colombelli P, Belotti Masserini A, Fantini F. Evaluation of quality of life in patients with systemic sclerosis by administering the SF-36 questionnaire. Reumatismo 2002; 54: 1227. In Italian.
  • 32
    Hellinger FJ. Expected utility theory and risky choices with health outcomes. Med Care 1989; 27: 2739.
  • 33
    Tsevat J. What do utilities measure? Med Care 2000; 38 Suppl 9: II1604.
  • 34
    King JT Jr, Tsevat J, Moossy JJ, Roberts MS. Preference-based quality of life measurement in patients with cervical spondylotic myelopathy. Spine 2004; 29: 127180.
  • 35
    Souchek J, Byrne MM, Kelly PA, O' Malley K, Richardson M, Pak C, et al. Valuation of arthritis health states across ethnic groups and between patients and community members. Med Care 2005; 43: 9218.